secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001326190-25-000037
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune's pemvidutide Phase 2b MASH trial hits primary endpoint; 59.1% resolution vs 19.1% placebo (p<0.0001)
--------------------------------------------------------------------------------

- MASH resolution without worsening fibrosis: 59.1% (1.2mg) and 52.1% (1.8mg) vs 19.1% placebo (p<0.0001).
- Fibrosis improvement not significant on primary, but AI analysis showed 30.6% achieving ≥60% reduction (p<0.001).
- Weight loss of 5.0% (1.2mg) and 6.2% (1.8mg) vs 1.0% placebo (p<0.001); trajectory not plateauing at 24 weeks.
- AE-related discontinuations <1.2% in pemvidutide arms vs 2.4% placebo; no SAEs related to study drug.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000037/0001326190-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000037/alt-20250626x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer